Publications by authors named "P Feyer"
Purpose: The aim of this review is to give an overview of the results of prospective and retrospective studies using allogenic reconstruction and postmastectomy radiotherapy (PMRT) in breast cancer and to make recommendations regarding this interdisciplinary approach.
Materials And Methods: A PubMed search was conducted to extract relevant articles from 2000 to 2024. The search was performed using the following terms: (breast cancer) AND (reconstruction OR implant OR expander) AND (radiotherapy OR radiation).
Article Synopsis
- The review aimed to assess the effectiveness of radiotherapy in managing brain metastases and leptomeningeal carcinomatosis in breast cancer patients and to provide treatment recommendations based on existing literature.
- A comprehensive search was conducted through PubMed for studies published between 1985 and May 2023, focusing on various types of radiotherapy for breast cancer-related brain metastases.
- Conclusions indicate that while specific radiotherapy guidelines show variability based on breast cancer subtypes, stereotactic radiosurgery is generally recommended for 1-4 brain metastases, while whole-brain radiotherapy is advised for multiple cases, especially in symptomatic patients, although treatment plans should be tailored and may include reevaluating local options after several weeks.
Background: Radiation dermatitis (RD) remains the most common side effect in radiation therapy (RT) with various pharmaceutical options available for prevention and treatment. We sought to determine pharmaceutical management patterns of radiation dermatitis among radiation oncology professionals.
Methods: We conducted a survey on RD among the German-speaking community of radiation oncologists inquiring for their opinion on preventive and therapeutic pharmaceutical approaches for acute RD.
Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures.
Geburtshilfe Frauenheilkd
August 2023
The S3-guideline on endometrial cancer, first published in April 2018, was reviewed in its entirety between April 2020 and January 2022 and updated. The review was carried out at the request of German Cancer Aid as part of the Oncology Guidelines Program and the lead coordinators were the German Society for Gynecology and Obstetrics (DGGG), the Gynecology Oncology Working Group (AGO) of the German Cancer Society (DKG) and the German Cancer Aid (DKH). The guideline update was based on a systematic search and assessment of the literature published between 2016 and 2020.
View Article and Find Full Text PDFArticle Synopsis
- - The S3-guideline for endometrial cancer, initially released in April 2018, underwent a comprehensive review and update from April 2020 to January 2022, as requested by German Cancer Aid and coordinated by prominent gynecological and oncology organizations in Germany.
- - The update focused on integrating new evidence and refining recommendations to enhance treatment approaches, emphasizing personalized therapies to minimize unnecessary radical surgeries and non-beneficial adjuvant treatments for low-risk patients.
- - The revised guideline aims to optimize care for high-risk patients by clarifying the roles of radical surgery and additional treatments, ultimately improving survival rates and quality of life, while serving as a foundation for certified gynecological cancer centers.